When the first preliminary annual survey on transplant activity was introduced by the European Group for Blood and Marrow Transplantation EBMT in 1990, a total 4234 transplants, 2137 allogeneic and 2097 autologous were reported. All procedures at that time were bone marrow transplants. 1 Within less than a decade major changes have occurred. Hematopoetic stem cell transplants have become established therapy for many congenital or acquired disorders of the hematopoietic system and for chemo-or radiosensitive malignancies. [2] [3] [4] [5] Stem cell source has changed from bone marrow to peripheral blood [6] [7] [8] and includes in most recent times cord blood. 9, 10 Donors for allogeneic transplants include HLA-identical siblings, HLA-mismatched relatives or unrelated volunteers. [11] [12] [13] The annual surveys have helped to describe the rapid increase in activity, to follow the changes in stem cell source and to assess quantitatively similarities or differences between individual European countries. 1, [14] [15] [16] [17] [18] Such objective data provide a basis for the annual recommendations on transplant indications. 19 The present report, illustrating the transplant activity in 1997, concentrates on the changes in indications since 1991. It focuses on absolute and relative increases according to the specific indication, separated for autologous and allogeneic transplants.
Patients and methods

Data collection
Data on transplant activity of the EBMT have been collected by standardized procedure since 1991, based on a preliminary analysis in 1990. 1 Members are requested to report the numbers of newly treated patients by indication, Neuroblastoma  2  1  1  1  35  165  6  5  206  211  Glioma  10  55  2  0  67  67  Soft tissue sarcoma  7  146  7  0  160  160  Germinal tumors  1  20  326  3  1  349  350  Breast cancer: stage 2  16  986  3  0  1005  1005  Breast cancer: stage 3  3  665  1  0  669  669  Breast cancer: inflammatory  1  158  7  0  166  166  Breast cancer: metastatic  1  2  12  767  7  3  786  789  Ewing  1  1  195  3  2  198  200  Lung cancer  81  1  0  82  82  Ovarian cancer  4  165  2  0  171  171  Other solid tumors  1  2  1  14  256  10  4  280  284  Non malignant disorders  657  113  770  Severe aplastic anemia ϩ  145  33  2  5  1  43  8  237  0  237  Fanconi  Thalassemia  100  15  7  122  0  122  SCID  34  2  19  6  16  3  80  0  80  Inborn errors  50  2  18  14  42  9  1  2  135  3  138  Auto immune disease  6  4  25  6  29  35  Others  42  12  1  5  2  13  2  5  74  2  77  81  158  Total  2123  1057  142  220  23  25  1023  138  829 11 021  349  4751 12 199 16 950 stem cell source and donor type (Table 1 ) on a questionnaire for the preceding year each January. The same information is sought from non-members, known to the investigators to perform transplants, from teams announced to EBMT by national organizations, neighboring teams or hospital administrators. The numbers for 1973, 1983 and 1991 are derived from previous reports. In 1993, all participating teams were additionally requested to report their patient numbers selectively for 1973 and 1983. 16 New teams beginning transplant programmes can thus be identified.
Definition of transplant numbers
The survey concentrates on numbers of patients receiving their first transplant during the calendar year 1997. Patients with second, double, triple or re-transplants are counted only once, thus multiple reporting is prevented. Included as exceptions are patients who were treated previously at another institution but who receive a first transplant at the reporting institution.
The additional procedures, re-or double transplants are collected in total, not specified by disease, to give an estimate of the total number of transplants.
Participating teams
473 teams were contacted in 32 European countries (= number in appendix) and, by EBMT tradition Israel, Saudi Arabia and Iran, to report all consecutive allogeneic and autologous transplants. All teams, with the exception of three, reporting in 1996 replied to the 1997 survey. An additional 12 teams did not reply. The teams are listed in the Appendix in alphabetical order of country, town, center and reporting physician. According to our estimate, based on contacts with national agencies and commercial providers, the report covers probably 95% of all allogeneic and near to 90% of all autologous blood or marrow transplants performed in Europe in 1997. Main deficiencies apply to small private institutions performing selectively some isolated transplants. According to personal communications, no blood or marrow transplants were performed in 1997 in Albania, Andorra, Armenia, Azerbaijan, Bosnia-Herzegovina, Bulgaria, Cyprus, Georgia, Iceland, Latvia, Liechtenstein, Lithuania, Malta, Moldovia, Monaco, Romania, San Marino, Ukraine and the Vatican.
Data validation
Reported data are entered in a computer file. Before data analysis, a printout is sent to each team for validation and verification. In countries with a national transplantation agency or registry, data are compared with the respective national co-ordinators. Discrepancies between reports to the national agency and EBMT are corrected by contacting teams in question for rectification.
Statistical analysis
Mean, median, range and coefficient of variation of numerical variables were calculated with the Excel spreadsheet.
Absolute and relative increase in transplant activity from 1991 to 1997 was calculated for each indication, separately for allogeneic and autolgous transplants. To determine the absolute increase, the number of transplants in 1991 was subtracted from the number of transplants in 1997; to determine the relative increase index (RII), the following formula was used: the fraction of transplants in 1997 of a Table 2 Number of patients transplanted with a first transplant and total number of transplant procedures in Europe 1997 given indication was divided by the fraction in 1991. For example, (n autologous transplants for breast carcinoma in 1997 divided by n total autologous transplants 1997) divided by (n autologous transplants for breast carcinoma in 1991 divided by n total autologous transplants 1991).
Results
Participating teams
457 participating teams from 31 countries reported to the survey in 1997 (96% of contacted teams). In 1973, when EBMT was founded, there were eight teams in five countries; in 1983, 97 teams in 17 countries. The increase from 143 teams in 1990 to 457 teams in 1997 is exclusively due to new teams starting transplant activities. The majority of teams, 57%, do both allogeneic and autologous transplants, 41% of teams restrict their activity to autologous, 2% to allogeneic transplants only.
Transplant figures
A total of 16 950 first transplants, 4751 allogeneic (28%) and 12 199 autologous (72%) were carried out in 1997. This represents an increase of 14% over 1996, when there were 14 593 transplants (4393 allogeneic; 10 200 autologous). This increase is due to new teams (16% increase) and greater number of transplants by established teams.
The increase in transplant activity from 16 transplants in 1973 (all allogeneic), to 1353 (880 allogeneic, 473 autologous) transplants in 1983 and 4961 in 1991 (2175 allogeneic, 2786 autologous) to the total of 16 950 in 1997 is illustrated in Figure 1 .
The total number of procedures, including re-and double transplants performed at the same 457 institutions was 18 923, 5032 allogeneic and 13 891 autologous transplants (Table 2 ). This restriction to numbers of new patients treated accounts for some of the discrepancies between reports from centers or national agencies when numbers of transplant procedures in total are reported.
Main indications
Indications for transplants in 1997 are listed in detail by donor type and donor source in 
Changes in indications
The relative proportion of main indications over the last 25 years in Europe is illustrated in Figures 2a and b The comparative absolute and relative increases in main indications for allogeneic and autologous transplants are listed in Table 3a . All indications have increased in absolute numbers. A relative increase in main indications was observed for autologous transplants in lymphoma (RII 1.11) and solid tumors (RII 1.79), for allogeneic transplants in lymphoma (RII 1.29).
More illustrative are the relative changes, if the disease indications are looked at individually as they are presented in Table 1 (Table 3b) .
The relative increases for autologous transplants focus on myelodysplastic syndromes (RII 3.77), myeloma (RII 2.12) and, most markedly, carcinoma of the breast (RII 6.37) . A relative decrease is observed for acute leukemias, Hodgkin's disease and some solid tumors, such as neuroblastoma (RII 0.46) and glioma (RII 0.27), for which indication even less transplants were performed in 1997 than in 1991.
Relative increases for allogeneic transplants were observed in myelodysplastic syndromes (RII 1.58), chronic lymphocytic leukemia (RII 1.33) and non-Hodgkin's lymphoma (RII 1.58), relative decreases for aplastic anemia (RII 0.68) and thalassemia (RII 0.55). In acute leukemias, there is a trend to perform transplants relatively more frequently at later stages of the disease than in first complete remission (RII 1.28 or RII 1.05 vs RII 0.86, or RII 0.87). Most remarkable is the constant figure of RII 1.00 for chronic myeloid leukemia, the most frequent and most accepted indication for an allogeneic transplant world-wide.
Donor type
Of the 16 950 transplants in 1997, 4751 were allogeneic (28%) and 12 199 autologous (72%). For the 4751 allogeneic transplants, donors were an HLA-identical sibling (67%) for 3180 recipients, HLA non-identical family mem-ber (8%) for 362 recipients, syngeneic twin (1%) for 48 recipients and an unrelated, volunteer donor (24%) for 1161 recipients.
Changes in donor type for the allogeneic transplants since 1973 are illustrated in Figure 3 . The proportion of unrelated transplants has increased from less than 1% in 1983 to 217 (10%) in 1991 and 1161 (24%) in 1997. 1 In contrast, the proportion of nonidentical family members as donors has shown a bimodal pattern. It increased steadily from 6% in 1973 to 10% in 1983, declined to 5% (101/2175) in 1991 and has risen again to 8% (362/4751) in 1997.
Stem cell source
Of the 12 199 autologous transplants in 1997, 829 (7%) were bone marrow derived, 11 021 (90%) from peripheral blood and 349 (3%) combined bone marrow and peripheral blood cells. In 1991, the proportion of autologous bone marrow derived cells was 85%. In 1991, no allogeneic peripheral blood stem cell transplants were reported. In 1997, 3311 (70%) of the 4751 allogeneic transplants were bone marrow derived, 1440 (30%) were using peripheral blood stem cells. The proportion of unrelated peripheral blood stem cell transplants is still low (138/1161, 12%) compared to 33% for the HLA-identical sibling donors, 61% for related non-identical donors and 52% for twin donors. This rapid shift occurring since 1991 is illustrated in Figure 3 .
A total of 86 allogeneic cord blood transplants were reported. This represents 2% of all allogeneic transplants in 1997. Detailed figures of cord blood transplants have only been collected since 1996.
Discussion
The present report, the seventh of a series, 1, [14] [15] [16] [17] [18] gives information on transplant numbers, transplant rates, stem cell sources, donor types and indications for blood and marrow transplants in Europe. It illustrates four major trends observed over the last 7 years: the number of transplants of blood and marrow progenitor cells is increasing rapidly, there is a shift from bone marrow to peripheral blood as stem cell source in autologous and allogeneic transplants, unrelated donor transplants are used increasingly and new indications for autologous transplants are emerging. The report underlines the rapid evolution of blood and marrow transplantation from an experimental undertaking 30 years ago 20,21 to established procedure today with near to 19 000 transplants in Europe and an estimated total of over 40 000 hematopoietic stem cell transplants world-wide in 1997.
Information on transplant activity invariably precedes analysis of outcome by many years. Nevertheless, in current times of evidence-based medicine objective criteria are warranted to determine procedure value. Subsequent collection of data, as in the repeated activity reports, provide a potential instrument. The comparison of transplant activities in different countries based on the number of transplants per number of inhabitants gives an estimate of the coefficient of variation in transplant activity for individual indications. There has been one quantitative approach, published recently.
22 It allows assessment consensus among physicians in Europe in a reproducible way.
The measure of absolute and relative increase or decrease over time for individual indications, as has been analyzed this year, is a new instrument to capture early trends objectively long before outcome data are available: a RII close to 1 documents that such indications are regarded as accepted indications during the observation period and that the absolute increase over time is mainly due to recruiting additional patients into new transplant programmes. A RIIϾ1 indicates emerging new indications, a RIIϽ1 fading indications.
The present data give us some clues: an absolute increase was observed for all indications except for neuroblastoma; the relative changes varied depending on indication and donor type. It is comforting to see that RII close to 1 are primarily found for disease indications with low CVs in previous reports, eg chronic myeloid leukemia for allogeneic transplants (RII 1.00) or non-Hodgkin's lymphoma for autologous transplants (RII 1.04). These indications are generally considered clear and accepted indications for hematopoietic stem cell transplants.
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High RII were observed in autologous transplants for MDS, multiple myeloma and carcinoma of the breast: all indications which have emerged over the last years. In contrast, autologous transplants for acute leukemias beyond first CR and for some solid tumors showed a decrease in RII. The relevance of these changes needs to be determined. They can indicate, that recent data do not favor transplants, that alternative treatments are becoming available or reduced interest in the procedure.
High RII were observed in allogeneic transplants for MDS, CLL and non-Hodgkin's lymphoma. The former reflect disease states frequently refractory to cure by conventional treatment, the latter a disease where a graft-versus-tumor effect, specifically graft-versus-lymphoma effect is being discussed. A relative decrease in severe aplastic anemia and thalassemia was noted. Two different potential explanations can be given for these relative decreases: alternative treatments, such as immunosuppression are available for patients with severe aplastic anemia. Thalassemia is restricted to certain geographic areas. Any increase in all regions is invariably associated with the relative decrease for indications with limited recruitment areas. Similarly, the trend to perform transplants for acute leukemias beyond first CR can be explained by the recognition of prognostic factors for good risk leukemias, hence the delay in transplant until later stages of the disease.
This report provides no information on outcome. These data are being collected and will be reported with due follow-up. The main goal of this report is to highlight the most significant changes in recent years. Knowledge of current activity and ongoing trends is essential for analysis and interpretation of outcome. It forms a basis for health care planning, setting up guidelines and recommendations for patient counselling. 
